Premium
Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus
Author(s) -
Kubo Shoji,
Tanaka Hiromu,
Takemura Shigekazu,
Yamamoto Satoshi,
Hai Seikan,
Ichikawa Tsuyoshi,
Kodai Shintaro,
Shinkawa Hiroji,
Sakaguchi Hiroki,
Tamori Akihiro,
Habu Daiki,
Nishiguchi Shuhei
Publication year - 2007
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/j.1872-034x.2007.00013.x
Subject(s) - lamivudine , hepatocellular carcinoma , medicine , hepatitis b virus , gastroenterology , adefovir , hepatitis b , virology , virus , oncology
Aim: Patients with high serum hepatitis B virus (HBV) DNA concentrations are at high risk of tumor recurrence after liver resection for HBV‐related hepatocellular carcinoma (HCC). Methods: Among 24 patients with high serum HBV DNA concentrations who underwent liver resection for HBV‐related HCC, postoperative lamivudine therapy was chosen by 14 (lamivudine group). The other 10 patients were controls. Results: Clinicopathologic findings did not differ between the groups. Tumor‐free survival rate after surgery was significantly higher in the lamivudine than the control group ( P = 0.0086). By univariate analysis, multiple tumors were also a risk factor for a short tumor‐free survival. By multivariate analysis, lack of lamivudine therapy and multiple tumors were independent risk factors for a short tumor‐free survival. In four patients YMDD mutant viruses were detected after beginning lamivudine administration; in two of them, adefovir dipivoxil was administered because of sustained serum alanine aminotransferase elevations. Conclusion: Lamivudine therapy improved tumor‐free survival rate after curative resection of HBV‐related HCC in patients with high serum concentrations of HBV DNA, although careful follow up proved necessary for the detection of YMDD mutant viruses.